Megan Yuen

Megan Yuen is a Clinical Trial Management Associate at Revolution Medicines, focusing on a Phase 1 KRAS solid tumors study since January 2024. Previously, Megan served as a Clinical Research Associate at FibroGen, Inc. from June 2020 to September 2023, managing a Phase 3 global study on Duchenne Muscular Dystrophy. Prior experience includes working as a Clinical Project Associate at Nektar Therapeutics on a Phase 1 US-only lymphoma study, and as a Senior Clinical Trial Specialist at Puma Biotechnology, where involvement in a Phase 3 global study on metastatic breast cancer occurred. Additionally, Megan worked at Gilead Sciences as a Clinical Project Assistant on both a Phase 1 US-only solid tumors study and a Phase 3 global gastric cancer study, and also held the position of Assistant Clinical Supplies Coordinator. Megan holds a degree in Biology with a concentration in Physiology from San Francisco State University, earned from 2010 to 2014.